Kynmobi

— THERAPEUTIC CATEGORIES —
  • Parkinsonism
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Kynmobi Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Apomorphine (as HCl) 10mg, 15mg, 20mg, 25mg, 30mg; sublingual films; contains sodium metabisulfite.

    Pharmacological Class

    Dopamine agonist (non-ergot).

    How Supplied

    Sublingual films—30; Titration kit—1 (2×10mg + 2×15mg + 2×20mg + 2×25mg + 2×30mg)

    Manufacturer

    Sunovion

    Generic Availability

    NO

    Kynmobi Indications

    Indications

    Acute, intermittent treatment of "off" episodes in Parkinson's disease.

    Kynmobi Dosage and Administration

    Adult

    See full labeling. Consider premedication with trimethobenzamide (300mg 3 times daily) starting 3 days prior to apomorphine initiation. Administer sublingually. Supervise 1st dose (monitor BP and pulse). Initially 10mg; if tolerated and effective, give up to max 5 times daily (as needed basis). If insufficient response, increase by 5mg increments and continued generally within 3 days, then reevaluate. Usual range: 10–30mg/dose. Separate doses by at least 2hrs. Max 30mg/single dose.

    Children

    Not established.

    Kynmobi Contraindications

    Contraindications

    Concomitant 5HT3 receptor antagonists (eg, alosetron, dolasetron, granisetron, ondansetron, palonosetron).

    Kynmobi Boxed Warnings

    Not Applicable

    Kynmobi Warnings/Precautions

    Warnings/Precautions

    Nausea/vomiting: consider pretreatment with antiemetic (trimethobenzamide) for up to 2 months (see Adult dosing). Sleep disorders (discontinue if significant daytime sleepiness occurs). Hallucinations/psychosis. Impulse control/compulsive behaviors; consider dose reduction or discontinue if urges develop. History of hypotension. Cardiovascular disease. Proarrhythmic conditions (eg, hypokalemia, hypomagnesemia, bradycardia, congenital QT prolongation). Sulfite allergy. Asthma. Severe renal impairment or ESRD: avoid. Severe hepatic impairment: avoid. Elderly. Pregnancy. Nursing mothers.

    Kynmobi Pharmacokinetics

    See Literature

    Kynmobi Interactions

    Interactions

    See Contraindications. Avoid alcohol, antiemetics with anti-dopaminergic actions (eg, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide). Hypotension potentiated with antihypertensives, vasodilators (esp. nitrates); monitor. May be antagonized by dopamine antagonists (eg, neuroleptics, metoclopramide). Caution with concomitant drugs that prolong the QT interval.

    Kynmobi Adverse Reactions

    Adverse Reactions

    Nausea, oral/pharyngeal soft tissue swelling/pain/paraesthesia, dizziness, somnolence; hypotension, syncope, falls, priapism, QTc prolongation, hypersensitivity reactions, withdrawal-emergent hyperpyrexia/confusion, fibrotic complications, hemolytic anemia.

    Kynmobi Clinical Trials

    See Literature

    Kynmobi Note

    Not Applicable

    Kynmobi Patient Counseling

    See Literature

    Images

    • Latest News Your top articles for Wednesday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More